<DOC>
	<DOCNO>NCT02557139</DOCNO>
	<brief_summary>Bioavailability , Phase I study evaluate clinical performance tablet formulation fast fed state , comparison capsule formulation feed state .</brief_summary>
	<brief_title>Bioavailability KD025 Healthy Male Subjects Completed UK</brief_title>
	<detailed_description>A 200 mg tablet formulation KD025 develop Quotient Clinical replace capsule formulation . This Phase I study evaluate clinical performance tablet formulation fast fed state , comparison capsule formulation feed state .</detailed_description>
	<criteria>Body mass index 18.0 30.0 kg/m2 , outside range , consider clinically significant investigator Good state health ( mentally physically ) indicate comprehensive clinical assessment ( detailed medical history complete physical examination ) , ECG laboratory investigation ( hematology , coagulation , clinical chemistry urinalysis ) Must willing able communicate participate whole study Must provide write informed consent Must agree use adequate method contraception 90 day post discharge Participation clinical research study within previous 3 month Subjects study site employee , immediate family member study site sponsor employee Subjects previously enrol study History drug alcohol abuse past 2 year Regular alcohol consumption &gt; 21 unit per week ( 1 unit = ½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) Current smoker smoke within last 12 month . A breath carbon monoxide read great 10 ppm screen Subjects suitable vein multiple venepunctures/cannulation assess investigator screen Clinically significant abnormal biochemistry , haematology , coagulation urinalysis judge investigator Positive drug abuse test result alcohol breath test Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) result History clinically significant cardiovascular , renal , hepatic , chronic respiratory GI disease may compromise subject safety interfere objective study judge investigator Subject history presence following : 1 . Active GI disease require therapy 2 . Hepatic disease and/or ALT AST &gt; 1.5 × ULN screen 3 . Renal disease and/or serum creatinine &gt; 1.5 × ULN screen 4 . Other condition know interfere absorption , distribution , metabolism excretion drug Subject QT interval correct use Fridericia 's formula ( QTcF ) interval &gt; 450 msec screen admission ECG Serious adverse reaction serious hypersensitivity drug formulation excipients Subject know sensitivity ROCK2 inhibitor agent constituent KD025 formulation Presence history clinically significant allergy require treatment , judge investigator . Hayfever allow unless active Donation loss great 400 mL blood within previous 3 month Subjects take , take , prescribed overthecounter drug ( 4 g per day paracetamol ) herbal remedy 14 day IMP administration Failure satisfy investigator fitness participate reason</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>